At the time of writing, Upstream Bio Inc [UPB] stock is trading at $8.78, up 4.28%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The UPB shares have gain 37.19% over the last week, with a monthly amount glided 2.69%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On November 05, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $75 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $38 on November 05, 2024.
For the past year, the stock price of Upstream Bio Inc fluctuated between $5.14 and $29.46. Currently, Wall Street analysts expect the stock to reach $75 within the next 12 months. Upstream Bio Inc [NASDAQ: UPB] shares were valued at $8.78 at the most recent close of the market. An investor can expect a potential return of 754.21% based on the average UPB price forecast.
Analyzing the UPB fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -35.65%, Pretax Profit Margin comes in at -29.38%, and Net Profit Margin reading is -29.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -4.93 and Total Capital is -0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.30 points at the first support level, and at 7.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.09, and for the 2nd resistance point, it is at 9.40.
Ratios To Look Out For
It is important to note that Upstream Bio Inc [NASDAQ:UPB] has a current ratio of 44.63. Also, the Quick Ratio is 44.63, while the Cash Ratio stands at 30.35.
Transactions by insiders
Recent insider trading involved Chimovits Erez, Director, that happened on Oct 15 ’24 when 0.82 million shares were purchased. Director, ORBIMED ADVISORS LLC completed a deal on Oct 15 ’24 to buy 0.82 million shares. Meanwhile, 10% Owner AI Upstream LLC bought 1.18 million shares on Oct 15 ’24.
